These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 25251308)

  • 21. Treatment of opioid dependence with buprenorphine: current update.
    Soyka M
    Dialogues Clin Neurosci; 2017 Sep; 19(3):299-308. PubMed ID: 29302227
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Food and Drug Administration approval of buprenorphine-naloxone for office treatment of addiction.
    Resnick RB
    Ann Intern Med; 2003 Feb; 138(4):360. PubMed ID: 12585846
    [No Abstract]   [Full Text] [Related]  

  • 23. Is daily supervised buprenorphine-naloxone dosing necessary?
    Kleinman RA; Nielsen S; Weiss RD
    BMJ; 2022 Aug; 378():e071467. PubMed ID: 35973725
    [No Abstract]   [Full Text] [Related]  

  • 24. New pharmacological tool approved for opioid addiction.
    Sansovich D
    HIV Clin; 2004; 16(3):9-11. PubMed ID: 15366107
    [No Abstract]   [Full Text] [Related]  

  • 25. Drugs approved for opiate dependence.
    FDA Consum; 2003; 37(1):6. PubMed ID: 12625293
    [No Abstract]   [Full Text] [Related]  

  • 26. Buprenorphine-containing treatments: place in the management of opioid addiction.
    Robinson SE
    CNS Drugs; 2006; 20(9):697-712. PubMed ID: 16953647
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A review of buprenorphine diversion and misuse: the current evidence base and experiences from around the world.
    Lofwall MR; Walsh SL
    J Addict Med; 2014; 8(5):315-26. PubMed ID: 25221984
    [TBL] [Abstract][Full Text] [Related]  

  • 28. THE RISE OF OPIOID ABUSE IN IOWA.
    Strickler K
    Iowa Med; 2015; 105(3):10-1. PubMed ID: 26591503
    [No Abstract]   [Full Text] [Related]  

  • 29. Using behavioral economics to predict opioid use during prescription opioid dependence treatment.
    Worley MJ; Shoptaw SJ; Bickel WK; Ling W
    Drug Alcohol Depend; 2015 Mar; 148():62-8. PubMed ID: 25622776
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Is buprenorphine-naloxone ready for prime time in the treatment of opioid addiction in managed care?
    Curtiss FR
    J Manag Care Pharm; 2008 Mar; 14(2):195-7. PubMed ID: 18331121
    [No Abstract]   [Full Text] [Related]  

  • 31. Office-based treatment of opioid-dependent patients.
    Ferner RE; Daniels AM
    N Engl J Med; 2003 Jan; 348(1):81-2; author reply 81-2. PubMed ID: 12510051
    [No Abstract]   [Full Text] [Related]  

  • 32. Steps physicians report taking to reduce diversion of buprenorphine.
    Yang A; Arfken CL; Johanson CE
    Am J Addict; 2013; 22(3):184-7. PubMed ID: 23617857
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Is the availability of buprenorphine/naloxone therapy for opioid-dependent inmates a necessity? ].
    Marco A; López-Burgos A; García-Marcos L; Gallego C; Antón JJ; Errasti A
    Rev Esp Sanid Penit; 2013 Feb; 15(3):105-13. PubMed ID: 24270319
    [TBL] [Abstract][Full Text] [Related]  

  • 34. How Massachusetts, Vermont, and New York Are Taking Action to Address the Opioid Epidemic.
    Hernandez Y; Meyers-Ohki S; Farkas S; Ball S; Leonard K; Rotrosen J; Saitz R
    Am J Public Health; 2018 Dec; 108(12):1621-1622. PubMed ID: 30403507
    [No Abstract]   [Full Text] [Related]  

  • 35. From the Food and Drug Administration.
    JAMA; 2002 Dec; 288(21):2678. PubMed ID: 12460076
    [No Abstract]   [Full Text] [Related]  

  • 36. The Time Is Now: The Role of Pharmacotherapies in Expanding Treatment for Opioid Use Disorder.
    Gordon AJ; Jenkins JA
    Subst Abus; 2015; 36(2):127-8. PubMed ID: 25826044
    [No Abstract]   [Full Text] [Related]  

  • 37. Risk reduction with buprenorphine-naloxone and methadone: patient's choice.
    Newman RG
    J Acquir Immune Defic Syndr; 2014 Dec; 67(5):e142. PubMed ID: 25197828
    [No Abstract]   [Full Text] [Related]  

  • 38. Treating opioid addiction with buprenorphine-naloxone in community-based primary care settings.
    Mintzer IL; Eisenberg M; Terra M; MacVane C; Himmelstein DU; Woolhandler S
    Ann Fam Med; 2007; 5(2):146-50. PubMed ID: 17389539
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Buprenorphine in the treatment of opiate dependence.
    Wesson DR; Smith DE
    J Psychoactive Drugs; 2010 Jun; 42(2):161-75. PubMed ID: 20648912
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Buprenorphine/naloxone versus methadone in opioid dependence: a longitudinal survey.
    Curcio F; Franco T; Topa M; Baldassarre C;
    Eur Rev Med Pharmacol Sci; 2011 Aug; 15(8):871-4. PubMed ID: 21845796
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.